MeSH tree: C08.381.540.140.500
Medical artificial intelligence (AI) faces a fundamental challenge: uncertainty quantification. Artificial neural networks are largely unaware of the limits of their training data and can become overconfident when confronted ...
Jun 23, 2026
0
6
Even as biomarker testing has become increasingly important for selecting the right lung cancer treatment, the time it takes to order these tests hasn't improved. Overall, the time from biopsy to biomarker results is about ...
Jun 22, 2026
0
6
An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumors in preclinical models of non-small cell lung cancer (NSCLC), including those resistant to a targeted therapy, a study led by UT Southwestern ...
Jun 11, 2026
0
8
The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations ...
May 29, 2026
0
8
In a study published in the Journal of Biomedical Science, researchers from National Taiwan University found that CASK helps promote the growth of non-small cell lung cancer (NSCLC) by regulating the EGFR–p21 signaling pathway. ...
May 27, 2026
0
3
A single blood test could help doctors predict how lung cancer patients will respond to treatment before therapy begins, researchers have found. University of Queensland-led research focused on non-small cell lung cancer ...
May 27, 2026
0
4
Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 receptor (GLP-1R) expression ...
May 22, 2026
0
22
A significant number of cancer patients—particularly those with more advanced cancers who are more likely to receive care at community hospitals, safety net hospitals, and rural medical centers—may have incomplete case information ...
May 14, 2026
0
3
The U.S. Food and Drug Administration (FDA) has approved Bizengri to treat an ultra-rare, aggressive cancer that forms in the bile ducts.
May 11, 2026
0
4
A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of Medicine found that setidegrasib, an investigational targeted therapy drug designed to eliminate a key ...
May 2, 2026
0
23
